Business
CareDx Announces Fourth Quarter and Full Year 2025 Financial Results
Full Year 2025 Total Revenue of $380 Million Increased 14% Year-Over-Year Expects Full Year 2026 Revenue of $420 Million to $444 Million BRISBANE,
About this update from Caredx, Inc.
[{"type":"text","content":"\nFull Year 2025 Total Revenue of $380 Million Increased 14% Year-Over-Year\n\n\nExpects Full Year 2026 Revenue of $420 Million to $444 Million\n\n\n BRISBANE, Calif.--(BUSINESS WIRE)--\nCareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high‑value healthcare solutions for transplant patients and caregivers, today reported financial results for the fourth quarter and full year ended December 31, 2025.\n\n\nFourth Quarter 2025 Financial Highlights\n\n\n\nRevenue of $108 million, an increase of 25% year-over-year\n\n\n\nTesting services revenue of $78 million, an increase of 23% year-over-year, and testing services volume of approximately 53,000, an increase of 17% year-over-year\n\n\n\nPatient and digital solutions revenue of $16.8 million and product revenue of $13.3 million, representing year-over-year growth of 47% and 17%, respectively\n\n\n\nAverage revenue per test of approximately $1,480 including approximately $5 million in prior period revenue\n\n\n\nGAAP net loss of $4 million, compared to GAAP net income of $88 million for the fourth quarter of 2024\n\n\n\nAdjusted EBITDA of $7 million, compared to $10 million for the fourth quarter of 2024; adjusted EBITDA includes approximately $7 million of operating expenses for compensation in lieu of equity grants for non-executives in the fourth quarter of 2025\n\n\n\nCash flow from operations of $21.4 million\n\n\n\nShare repurchases of $12 million during the quarter of 773,000 shares at an average price of $15.79 per share\n\n\n\nRecent Business Highlights\n\n\n\nPublished the third SHORE registry manuscript in the Journal of Heart and Lung Transplantation, reinforcing the clinical evidence for HeartCare and the prognostic value of combined molecular testing\n\n\n\nAdvanced Epic Aura integrations, with seven transplant centers live and approximately twenty implementations underway, supporting improved workflow integration across transplant programs\n\n\n\nLaunched ImmuneScape™ through a strategic collaboration with 10x Genomics, establishing a multiomics discovery platform to inform next‑generation precision transplant diagnostics\n\n\n\nAnnounced pivotal validation data for AlloHeme™, advancing CareDx’s expansion beyond solid organ transplantatio...